Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

The first portable monitoring medical device providing accurate prognosis for patients with circulatory failure

Project description

Innovative platform for microcirculatory function monitoring

Microcirculatory failure affects millions of patients worldwide, leading to high casualties and significant societal and economic impacts. Existing medical devices prevent physicians from diagnosing if the patients are clinically dead. The EU-funded Oximonitor project proposes a unique solution that monitors microcirculatory function with precision measuring of oxygen delivery. This solution is a pioneering, validated, patented and non-invasive point-of-care integrated platform. The platform incorporates the mLab hardware that collects data from the surface of the patient’s skin and a cloud computing software based on machine learning that collects and analyses the data generated by the patient’s interpretation report.

Objective

Microcirculatory failure (the inability to deliver sufficient O2 to the cells of the body), is a symptom from several health conditions affecting millions of individuals worldwide (e.g. heart failure, neonatal asphyxia or sepsis). The societal and financial impact of these conditions is enormous, as exemplified by patients in need of cardiac and respiratory support (such as extracorporeal membrane oxygenation life support or ECMO), with only 17% of survivors, while costing up to 1.35 M€ for a 1-year treatment. Specialists cannot predict if these patients are clinically dead or can recover because available medical devices do not allow to monitoring patient´s microcirculatory function.
To solve this, at ODI Medical (a Norwegian start-up company) we have developed OXIMONITOR, the first-ever proof-of-concept validated, patented and non-invasive point of care (POC) integrated platform used bedside that accurately monitors microcirculatory function by quantifying O2 delivery and allows to assess the effectiveness of the patient´s treatment of choice, all in a user-friendly manner. OXIMONITOR incorporates: (1) The mLab hardware which creates an “optical fingerprint” of the patient’s circulatory function by collecting data from the surface of the patient’s skin, the conjunctiva or even sublingually. (2) The cLab; a Cloud computing software based on machine learning technology that collects and analyses the data generating the patient´s interpretation report, which is sent back to the clinical site through a user-friendly dashboard for decision-making.
The market of cardiac monitoring (our first clinical application) will reach €22 billion by 2022 at a CAGR of 3.9% (2017-2022). With OXIMONITOR we will contribute to the viability of our company, generating a cumulative profit of 34.39 M€ (ROI of 12.75) and growing our staff count 400% by 2023. Likewise, the IP generated by this project will allow us to expand the number of clinical applications using our platform.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

ODI MEDICAL AS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 50 000,00
Address
OSLO SCIENCE PARK, GAUSTADALLEEN 21
0349 OSLO
Norway

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Norge Oslo og Viken Oslo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 71 429,00
My booklet 0 0